BAP31, a promising target for the immunotherapy of malignant melanomas

PURPOSE: Malignant melanoma’s (MM) incidence is rising faster than that of any other cancer in the US and the overall survival at 5 years is less than 10%. B cell associated protein 31 (BAP31) is overexpressed in most MMs and might be a promising target for immunotherapy of this disease. EXPERIMENTA...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Shaojuan, Wang, Fuli, Fan, Li, Wei, Yuying, Li, Haitao, Sun, Yuanjie, Yang, Angang, Jin, Boquan, Song, Chaojun, Yang, Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405826/
https://www.ncbi.nlm.nih.gov/pubmed/25903101
http://dx.doi.org/10.1186/s13046-015-0153-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405826/
https://www.ncbi.nlm.nih.gov/pubmed/25903101
http://dx.doi.org/10.1186/s13046-015-0153-6

Ejemplares similares